Home › Research › Disease mechanisms
Emerging Role of Oligodendrocytes Malfunction in the Progression of Alzheimer's Disease
Kinga Tylek, Agnieszka Basta‐Kaim. Journal of Neuroimmune Pharmacology, 2025-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by hallmark pathologies such as amyloid-beta (Aβ) plaque accumulation, tau hyperphosphorylation, and progressive neuronal dysfunction. While much attention has focused on neurons and microglia, recent studies underscore the significant yet understudied roles of oligodendrocytes (OL) and oligodendrocyte precursor cells (OPC) in AD pathology. OL, responsible for myelin production and maintenance, are impaired early in AD, contributing to demyelination, synaptic dysfunction, and cognitive decline. Emerging evidence reveals that Aβ and tau pathology disrupt OPC differentiation and induce senescence, exacerbating neuroinflammation and reducing remyelination potential. Demyelination precedes overt AD symptoms, positioning it as a potential early biomarker. Furthermore, animal models reveal that OPC density and function deteriorate with age, particularly in the presence of Aβ plaques, highlighting their vulnerability in the AD environment. Transcriptomic studies also link cholesterol biosynthesis and lipid metabolism dysregulation in OPC to AD progression, emphasizing the intricate relationship between OL, metabolic processes, and amyloid toxicity. Additionally, the identification of disease-associated oligodendrocytes (DAO), characterized by altered gene expression and proximity to Aβ plaques, highlights their involvement in neuroinflammation and APP processing. This review synthesizes recent insights into OL and OPC dysfunction in AD, focusing on their roles in neuroinflammation, Aβ clearance, and myelin integrity. It discusses the potential of targeting OL and OPC pathways, such as enhancing remyelination and mitigating senescence, as novel therapeutic strategies. By addressing gaps in our understanding of OL dynamics, this work sheds light on their critical contributions to AD pathology and sets the stage for future research and intervention.
What this study adds
Evidence grade: Low
This review highlights the understudied roles of oligodendrocytes and their precursor cells in Alzheimer's disease, including demyelination, impaired remyelination and links to cholesterol and lipid metabolism. It summarizes emerging evidence and does not report a treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tylek, K., & Basta‐Kaim, A. (2025). Emerging Role of Oligodendrocytes Malfunction in the Progression of Alzheimer's Disease. Journal of Neuroimmune Pharmacology. https://doi.org/10.1007/s11481-025-10236-z
Vancouver
Tylek K, Basta‐Kaim A. Emerging Role of Oligodendrocytes Malfunction in the Progression of Alzheimer's Disease. Journal of Neuroimmune Pharmacology. 2025. doi:10.1007/s11481-025-10236-z. PMID: 40887534.
BibTeX
@article{tylek2025-40887534,
author = {Tylek, Kinga and Basta‐Kaim, Agnieszka},
title = {{Emerging Role of Oligodendrocytes Malfunction in the Progression of Alzheimer's Disease}},
journal = {Journal of Neuroimmune Pharmacology},
year = {2025},
doi = {10.1007/s11481-025-10236-z},
pmid = {40887534},
url = {https://doi.org/10.1007/s11481-025-10236-z}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- While much attention has focused on neurons and microglia, recent studies underscore the significant yet understudied roles of oligodendrocytes (OL) and oligodendrocyte precursor cells (OPC) in AD pathology.
Why it matters
This review highlights the understudied roles of oligodendrocytes and their precursor cells in Alzheimer's disease, including demyelination, impaired remyelination and links to cholesterol and lipid metabolism. It summarizes emerging evidence and does not report a treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Neuroimmune Pharmacology) |
| Journal's citation record | 1 / 4 | Journal of Neuroimmune Pharmacology: journal h-index 108 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 7.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Agnieszka Basta‐Kaim: h-index 40 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Polish Academy of Sciences: institution h-index 593 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40887534) |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s11481-025-10236-z
- PubMed: 40887534
- Original source →
- Free full text: Journal of Neuroimmune Pharmacology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Disease mechanisms from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.